CoChat

(S)‐Emopamil, a novel calcium channel blocker and serotonin S 2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat

Nakayama, Hitoshi, Ginsberg, Myron D., Dietrich, W. Dalton · 1988 · Neurology
Cited by 135

The DOI matches its Crossref record.

Abstract

(S)-Emopamil is a novel calcium channel blocker of the phenylalkylamine class, with superior blood-brain permeability and potent serotonin S2 antagonist activity. In this study, we investigated the effects of (S)-emopamil on the histopathologic consequences of permanent middle cerebral artery (MCA) occlusion in anesthetized Sprague-Dawley rats. In three treatment protocols, intraperitoneal (S)-emopamil therapy was begun either 30 minutes prior to, immediately after, or 1 hour after MCA occlusion. Nontreated and saline-treated control groups were also studied. Cortical infarct volumes in nontreated and saline-treated control rats were 85 +/- 22 and 66 +/- 19 mm3 (mean +/- SD), respectively, and did not differ statistically from one another. Corresponding cortical infarct volume values in (S)-emopamil-pretreated rats, and in rats with post-treatment at 0 hours and 1 hour, were 33 +/- 23, 29 +/- 14, and 27 +/- 16 mm3, respectively; each of these was significantly smaller than control values. In contrast to the neocortex, striatal infarct volume was not altered by (S)-emopamil treatment. The results of this study demonstrate the marked therapeutic efficacy of (S)-emopamil in focal cortical infarction, even when treatment is delayed for 1 hour following MCA occlusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.38.11.1667

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 135

Metadata

Authors
Nakayama, H., Ginsberg, M. D., & Dietrich, W. D.
Venue
Neurology
Published
1988-11
Volume
38
Issue
11
Pages
1667-1667
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1991497833
Cited by
135
References
0
FWCI
7.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: (S)‐Emopamil, a novel calcium channel blocker and serotonin S 2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. https://app.cochat.ai/papers/10.1212/wnl.38.11.1667
The paper
Nakayama, H., Ginsberg, M. D., & Dietrich, W. D. (1988). (S)‐Emopamil, a novel calcium channel blocker and serotonin S 2 antagonist, markedly reduces infarct size following middle cerebral artery occlusion in the rat. Neurology. https://doi.org/10.1212/wnl.38.11.1667

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.